Jon Arnason

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon et al. · The Lancet · 2020 · 2.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +5

Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease

Katharina Lahl, Christoph Loddenkemper, Cathy E. Drouin et al. · The Journal of Experimental Medicine · 2007 · 905 citations · Full text

T-regulatory Cell, Immunology, Immune Regulation +18

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 704 citations

Second-line Treatment, Salvage Chemotherapy, Interim Analysis +9

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 327 citations · Full text

Immunology, Pathology, Global Phase 3 +20

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Benjamin L. Lampson, Siddha Kasar, Tiago R. Matos et al. · Blood · 2016 · 284 citations · Full text